TRANSFORMING SEPSIS TREATMENT
We are dedicated to saving the lives of critically ill patients with sepsis by pioneering innovative treatments and research.
VISION
We’re changing the way the world treats sepsis
Sepsis affects ~50 million people/year and remains the leading cause of global mortality, with ~11 million deaths each year. For sepsis survivors, the ongoing health burden can be significant.
Our vision is to leverage groundbreaking research and innovative therapies to improve survival rates and health outcomes for patients with sepsis.
CLINICAL TRIALS
PATENTED PH-BALANCED FORMULATION
Sepsis is characterised by life-threatening falls in blood pressure (hypotension) leading to multi-organ dysfunction.
​
We are pioneering the use of our patented pH-balanced formulation of an intravenous mega dose of sodium ascorbate to reverse sepsis induced multi-organ dysfunction.
RESULTS OF PHASE 1A CLINICAL TRIALS
In our Phase 1a randomised, double blinded clinical trial in 30 patients with septic shock at Austin Health ICU, we found that our patented formulation was safe and produced several physiological signals of benefit in critically ill patients.
​
The formulation was:
-
safe and feasible for use;
-
significantly increased cumulative urinary output;
-
significantly reduced requirements for blood pressure maintaining drugs; and
-
showed signs of improved multi organ function.
PHASE 1B MULTI-CENTRE CLINICAL TRIAL AROUND AUSTRALIA
Following promising Phase I trial results, this multi-centre clinical trial will advance our patented drug to 10 hospital sites across Victoria, South Australia, New South Wales and Queensland.
​​
We are funded for a phase 2 clinical trial by a $4.9 million Medical Research Future Fund (MRFF) grant by the Federal government to advance our drug across every state and territory across mainland Australia.
WHY PANASCEA
Sepsis breakthrough therapy on the horizon
We are leading groundbreaking research on a potentially life-saving treatment for sepsis. Our patented formulation has shown very promising results and we are advancing our investigations to assess efficacy in multi-centre clinical trials.
​​
We believe our first-in-class therapy could transform sepsis management globally.
INDUSTRY
Our
Research Collaborations
Scientists and clinicians from Australia's leading medical research institutes and public hospitals will work together over the next five years to advance this critical work.
FLOREY INSTITUTE
MONASH UNIVERSITY
PETER MAC
DOHERTY INSTITUTE